Cidara Therapeutics, Inc. announced on March 19, 2025, its participation in a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The company's Chief Scientific Officer, Les Tari, Ph.D., joined the 'Other pharmaceuticals as preventive tools' panel.
The meeting, titled 'What research is important to prepare and respond to H5N1 influenza outbreaks,' focused on coordinating efforts for research preparedness. CD388, Cidara's long-acting antiviral influenza preventative, has demonstrated potent activity against all influenza A and B strains, including H5N1, in preclinical studies.
This engagement with global leaders underscores the potential of CD388 as a universal preventative for influenza outbreaks, particularly in light of the growing threat of H5N1. Its immune-independent activity makes it a promising option for broad seasonal and pandemic influenza protection.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.